				<section class="content container">
					<p class="boxed blue">ABILIFY<sup>&reg;</sup> (aripiprazole) is indicated for the treatment of schizophrenia in adults.</p>
					<section class="resource-section peer-perspectives-video">
						<div class="resource-title">
							<p>Reprint Library</p>
						</div>
						<div class="resource-content">
							<p>Articles for Adult Schizophrenia</p>
							<ul>
								<li>
									<h2>Aripiprazole for the Prevention of Relapse in Stabilized Patients With Chronic Schizophrenia: A Placebo-Controlled 26-Week Study<br><em>J Clin Psychiatry</em>. 2003;64(9):1048-1056.<br>Pigott TA, Carson WH, Saha AR, et al.</h2>
									<p>A 26-week, randomized, placebo-controlled study conducted to evaluate the efficacy and safety of oral ABILIFY (15 mg/day) in preventing relapse in patients with Schizophrenia who were stabilized on other antipsychotic medications for 3 months or longer and were discontinued from these other medications and given ABILIFY or placebo and observed for relapse. ABILIFY significantly delayed the time to relapse and demonstrated significant reduction in risk of relapse compared to placebo. Adverse events (&GreaterEqual;5% and greater than placebo) observed in subjects receiving ABILIFY included insomnia (ABILIFY 42.5%, placebo 39.9%), tremor (ABILIFY 8.5%, placebo 1.3%), akathisia (ABILIFY 7.8%, placebo 6.5%), vomiting (ABILIFY 5.9%, placebo 3.3%), and nausea (ABILIFY 5.2%, placebo 3.3%).<br><a href="#">Download full article (PDF)</a><br><a href="#">Download IMPORTANT SAFETY INFORMATION</a><br><a href="#">Download US FULL PRESCRIBING INFORMATION, including Boxed WARNINGS</a></p>
								</li>
							</ul>
						</div>
					</section>
				</section>
			
				<?php include '../inc/isi.php'; ?>